Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haya Lorberboum-Galski

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Expert Opinion on Drug Delivery|April 2, 2011
Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseasesHaya Lorberboum-Galski
Expert Opinion on Drug Delivery|May 6, 2009
TAT-based drug delivery system--new directions in protein delivery for new hopes?Matan Rapoport, Haya Lorberboum-Galski
The Journal of Biological Chemistry|June 15, 2007
A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuriaRonen Eavri, Haya Lorberboum-Galski
Clinical Immunology (Orlando, Fla.)|February 14, 2004
Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactionsRuth Belostotsky, Haya Lorberboum-Galski
Frontiers in Microbiology|December 25, 2014
Combining flagellin and human β-defensin-3 to combat bacterial infectionsOfra Sabag, Haya Lorberboum-Galski
Expert Review of Anticancer Therapy|January 30, 2004
Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteinsAhmi Ben-Yehudah, Haya Lorberboum-Galski
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2008
TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiencyMatan Rapoport, Ann Saada, Orly Elpeleg, et al.
Cancer|June 14, 2012
Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignanciesRotem Kedar, Ofra Sabag, Michal Licthenstein, et al.
Molecular Medicine (Cambridge, Mass.)|May 15, 2013
Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cellsDana Marcus, Michal Lichtenstein, Ann Saada, et al.
International Journal of Cancer|June 23, 2010
IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathwayInna Grodzovski, Michal Lichtenstein, Hanan Galski, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Delivery|April 2, 2011
Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseasesHaya Lorberboum-Galski
Expert Opinion on Drug Delivery|May 6, 2009
TAT-based drug delivery system--new directions in protein delivery for new hopes?Matan Rapoport, Haya Lorberboum-Galski
The Journal of Biological Chemistry|June 15, 2007
A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuriaRonen Eavri, Haya Lorberboum-Galski
Clinical Immunology (Orlando, Fla.)|February 14, 2004
Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactionsRuth Belostotsky, Haya Lorberboum-Galski
Frontiers in Microbiology|December 25, 2014
Combining flagellin and human β-defensin-3 to combat bacterial infectionsOfra Sabag, Haya Lorberboum-Galski
Expert Review of Anticancer Therapy|January 30, 2004
Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteinsAhmi Ben-Yehudah, Haya Lorberboum-Galski
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2008
TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiencyMatan Rapoport, Ann Saada, Orly Elpeleg, et al.
Cancer|June 14, 2012
Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignanciesRotem Kedar, Ofra Sabag, Michal Licthenstein, et al.
Molecular Medicine (Cambridge, Mass.)|May 15, 2013
Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cellsDana Marcus, Michal Lichtenstein, Ann Saada, et al.
International Journal of Cancer|June 23, 2010
IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathwayInna Grodzovski, Michal Lichtenstein, Hanan Galski, et al.
Pageof 4